Results 21 to 30 of about 8,597,475 (170)

Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration

BMJ Open Ophthalmology
Purpose Age-related macular degeneration (AMD) remains the leading cause of blindness in developed countries. There are many different intravitreal anti-vascular endothelial growth factor (VEGF) drugs available for the treatment of neovascular AMD (nAMD).
Siegfried Priglinger, Jakob Siedlecki, Benedikt Schworm, Franziska Eckardt, Michael Hafner, Ben Asani, Caspar Liesenhoff, Alexander Kufner, Johannes Benedikt Schiefelbein   +8 more
doaj   +2 more sources

Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration from China: 48-week results from the PULSAR trial [PDF]

International Journal of Retina and Vitreous
Background PULSAR (NCT04423718) was a global, phase 3, randomized, double-masked, non-inferiority study of adults with neovascular age-related macular degeneration (nAMD).
Xiaodong Sun, Hong Dai, Youxin Chen, Xufang Sun, Liming Tao, Jun Xiao, Mei Han, Mingwei Zhao, Li Wang, Andrea Schulze, Ursula Maria Schmidt-Ott, Min Zhao, Xin Zhang, Zhaohong Wang, Sergio Leal, Wenbin Wei, on behalf of the PULSAR investigators   +16 more
doaj   +2 more sources

Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US [PDF]

Ophthalmology and Therapy
This is a summary of the original article “Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US”.
Andreas Kuznik, Anna Coughlan, Amy Pinsent, Hector Toro-Diaz, Steven Sherman, Nimesh A. Patel   +5 more
doaj   +2 more sources

Efficacy of Aflibercept 8 mg in Pretreated Age-Related Macular Degeneration. [PDF]

J Clin Med
This study aims to evaluate the real-world efficacy and safety of aflibercept 8 mg intravitreal injections (IVTs) in pretreated patients with neovascular age-related macular degeneration (nAMD) throughout the first three IVTs. Background: Established anti-vascular-endothelial-growth-factor (anti-VEGF) therapies positively impact the progression of nAMD
Palm C, Zweifel SA, Gabathuler F, Cozzi M, Fasler K.   +4 more
europepmc   +3 more sources

Initial Response of Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration

Journal of Clinical Medicine
Objectives: To assess the initial anatomical and functional outcomes of switching to aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD) previously treated with anti-vascular endothelial growth factor (VEGF) therapy. Methods: Patients with nAMD previously treated with anti-VEGF drugs were switched to aflibercept 8 mg ...
Chikako Hara, Satoko Fujimoto, Yoko Fukushima, Kaori Sayanagi, Kentaro Nishida, Kazuichi Maruyama, Shigeru Sato, Takatoshi Maeno, Kohji Nishida   +8 more
openaire   +3 more sources

Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema [PDF]

Ophthalmology and Therapy
Introduction Aflibercept 8 mg and faricimab provide effective anatomical and visual acuity improvements in diabetic macular edema (DME), although functional recovery may not be fully captured by conventional endpoints.
Feliciana Menna, Mattia Calabro, Antonio Guillot, Laura De Luca, Alessandro Meduri, Antonio Baldascino, Stefano Lupo, Enzo Maria Vingolo   +7 more
doaj   +2 more sources

Real-world six-month outcomes after switching from aflibercept 2 mg to aflibercept 8 mg for neovascular age-related macular degeneration. [PDF]

Jpn J Ophthalmol
Abstract Purpose To investigate 6-month outcomes in eyes with neovascular age-related macular degeneration (nAMD) switched from intravitreal aflibercept 2 mg to intravitreal aflibercept 8 mg.
Kindo H, Hosokawa MM, Ouchi C, Matoba R, Morita T, Hayashi J, Morizane Y.   +6 more
europepmc   +5 more sources

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema [PDF]

Therapeutic Advances in Ophthalmology
Summary What is this summary about? This is a summary of a publication about the 2-year (96-week) results from the PHOTON study, which was published in Ophthalmology . Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes.
Diana V. Do, Charles C. Wykoff, Sobha Sivaprasad, David M. Brown, David S. Boyer, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, András Seres, Sergio Leal, Robert Vitti, Karen W. Chu, Kimberly Reed, Yenchieh Cheng, Rafia Bhore, Zhanying Bai, Ursula Schmidt-Ott, Thomas Schmelter, Andrea Schulze, Zoran Hasanbasic, Peter J. Morgan-Warren, Xin Zhang, Alyson J. Berliner   +23 more
doaj   +2 more sources

Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US

Ophthalmology and Therapy
Introduction The aim of this study was to compare the estimated direct and indirect costs with aflibercept 8 mg and faricimab in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) over 5 years.
Andreas Kuznik, Anna Coughlan, Amy Pinsent, Hector Toro-Diaz, Steven Sherman, Nimesh Patel   +5 more
doaj   +2 more sources

Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series

BMJ Open Ophthalmology
Objective This real-world retrospective case series evaluates the safety and efficacy of aflibercept 8 mg in patients diagnosed with neovascular age-related macular degeneration (nAMD).Methods and analyses Treatment-naïve or treatment-experienced ...
David A Eichenbaum, Deepak Sambhara, Priya Vakharia   +2 more
doaj   +3 more sources